BioMarin Pharmaceutical's total assets for Q3 2024 were $6.85B, a decrease of -3.06% from the previous quarter. DE:BM8 total liabilities were $1.44B for the fiscal quarter, a -19.26% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.